IXC — Invex Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- AU$7.89m
- AU$3.87m
- AU$0.18m
Annual balance sheet for Invex Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 29.3 | 22.5 | 6.03 | 5.38 | 4.02 |
| Net Total Receivables | 0.146 | 0.334 | 0.095 | 0.093 | 0.047 |
| Total Current Assets | 29.5 | 22.8 | 6.12 | 5.47 | 4.06 |
| Total Assets | 29.5 | 22.8 | 6.12 | 5.47 | 4.06 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 1 | 1.57 | 0.432 | 0.221 | 0.153 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 1 | 1.57 | 0.432 | 0.221 | 0.153 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 28.5 | 21.2 | 5.69 | 5.25 | 3.91 |
| Total Liabilities & Shareholders' Equity | 29.5 | 22.8 | 6.12 | 5.47 | 4.06 |
| Total Common Shares Outstanding |